Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1974 Apr;5(4):403–408. doi: 10.1128/aac.5.4.403

Evaluation of Isoprinosine in Experimental Human Rhinovirus Infection

Donald M Pachuta a, Yasushi Togo a, Richard B Hornick a, Andrew R Schwarts a,1, Suketami Tominaga a
PMCID: PMC428983  PMID: 15825396

Abstract

The prophylactic efficacy of isoprinosine was evaluated in a double-blind fashion in volunteers challenged with two types of rhinovirus. In the rhinovirus 44 and 32 trials, each of 9 men received a placebo, and eight and 11 men received the drug, respectively. Oral isoprinosine, 6 g a day, was given for 2 days prior to intranasal challenge with 100 mean tissue culture infective doses of the virus and for 7 postchallenge days. In both trials the occurrence and severity of colds were greater in the placebo group, but the difference between the two groups was not significant. Higher antibody titers for both viruses and a greater number of rhinovirus 32 isolations were demonstrated in the drug group but without statistically significant differences. The prophylactic isoprinosine treatment may suppress the cold syndrome, but its effect was not convincingly apparent.

Full text

PDF
406

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang T. W., Weinstein L. Antiviral activity of isoprinosine in vitro and in vivo. Am J Med Sci. 1973 Feb;265(2):143–146. doi: 10.1097/00000441-197302000-00005. [DOI] [PubMed] [Google Scholar]
  2. Fareed G. C., Tyler H. R. The use of isoprinosine in patients with amyotrophic lateral sclerosis. Neurology. 1971 Sep;21(9):937–940. doi: 10.1212/wnl.21.9.937. [DOI] [PubMed] [Google Scholar]
  3. Glasgow L. A., Galasso G. J. Isoprinosine: lack of antiviral activity in experimental model infections. J Infect Dis. 1972 Aug;126(2):162–169. doi: 10.1093/infdis/126.2.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gordon P., Brown E. R. The antiviral activity of isoprinosine. Can J Microbiol. 1972 Sep;18(9):1463–1470. doi: 10.1139/m72-224. [DOI] [PubMed] [Google Scholar]
  5. Longley S., Dunning R. L., Waldman R. H. Effect of isoprinosine against challenge with A(H3N2)-Hong Kong influenza virus in volunteers. Antimicrob Agents Chemother. 1973 Apr;3(4):506–509. doi: 10.1128/aac.3.4.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Muldoon R. L., Mezny L., Jackson G. G. Effect of isoprinosine against influenza and some other viruses causing respiratory diseases. Antimicrob Agents Chemother. 1972 Sep;2(3):224–228. doi: 10.1128/aac.2.3.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Soto A. J., Hall T. S., Reed S. E. Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers. Antimicrob Agents Chemother. 1973 Mar;3(3):332–334. doi: 10.1128/aac.3.3.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Togo Y., Schwartz A. R., Hornick R. B. Failure of a 3-substituted triazinoindole in the prevention of experimental human rhinovirus infection. Chemotherapy. 1973;18(1):17–26. doi: 10.1159/000221243. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES